MX378107B - AN A3 ADENOSINE RECEPTOR BINDER FOR USE IN THE TREATMENT OF ECTOPIC FAT ACCUMULATION. - Google Patents
AN A3 ADENOSINE RECEPTOR BINDER FOR USE IN THE TREATMENT OF ECTOPIC FAT ACCUMULATION.Info
- Publication number
- MX378107B MX378107B MX2018006026A MX2018006026A MX378107B MX 378107 B MX378107 B MX 378107B MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 378107 B MX378107 B MX 378107B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- fat accumulation
- ligand
- ectopic fat
- present disclosure
- Prior art date
Links
- 238000009825 accumulation Methods 0.000 title abstract 5
- 101150046889 ADORA3 gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 2
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 2
- 208000010706 fatty liver disease Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
The present disclosure concerns A<sub>3</sub>AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the present disclosure is the use of A<sub>3</sub>AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprising the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the present disclosure provides the use of an A<sub>3</sub>AR agonist, such as 2-Chloro-N<sup>6</sup>-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL242723A IL242723B (en) | 2015-11-23 | 2015-11-23 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
| PCT/IL2016/051258 WO2017090036A1 (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006026A MX2018006026A (en) | 2019-01-28 |
| MX378107B true MX378107B (en) | 2025-03-10 |
Family
ID=57485841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006026A MX378107B (en) | 2015-11-23 | 2016-11-22 | AN A3 ADENOSINE RECEPTOR BINDER FOR USE IN THE TREATMENT OF ECTOPIC FAT ACCUMULATION. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10780106B2 (en) |
| EP (1) | EP3380104B1 (en) |
| JP (2) | JP6980655B2 (en) |
| KR (1) | KR102103657B1 (en) |
| CN (1) | CN108367016B (en) |
| BR (1) | BR112018010391A8 (en) |
| CA (1) | CA3005961C (en) |
| DK (1) | DK3380104T3 (en) |
| ES (1) | ES2848150T3 (en) |
| HR (1) | HRP20210020T1 (en) |
| HU (1) | HUE053558T2 (en) |
| IL (3) | IL242723B (en) |
| LT (1) | LT3380104T (en) |
| MX (1) | MX378107B (en) |
| PL (1) | PL3380104T3 (en) |
| PT (1) | PT3380104T (en) |
| RS (1) | RS61372B1 (en) |
| SI (1) | SI3380104T1 (en) |
| WO (1) | WO2017090036A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for managing cytokine release syndrome |
| IL264112A (en) * | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
| CN121045296A (en) | 2024-05-31 | 2025-12-02 | 康菲特生物制药有限公司 | Process for preparing nalmod nuonsen |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| AU7331094A (en) | 1993-07-13 | 1995-02-13 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | A3 adenosine receptor agonists |
| AU1399297A (en) | 1996-01-24 | 1997-08-20 | Sumitomo Chemical Company, Limited | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production |
| EP1019427A1 (en) | 1997-07-29 | 2000-07-19 | Medco Research, Inc. | N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| WO1999020284A1 (en) | 1997-10-23 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| CN1259056C (en) * | 2001-01-16 | 2006-06-14 | 坎-菲特生物药物有限公司 | Use of adenosine A3 receptor agonist for inhibition of viral replication |
| JP5414277B2 (en) | 2006-01-26 | 2014-02-12 | ザ・ガバメント・オブ・ジ・ユナイテッド・ステイツ・オブ・アメリカ・レプリゼンテッド・バイ・ザ・セクレタリー・ディパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ | A3 adenosine receptor allosteric modulator |
| ES2490606T3 (en) | 2007-10-15 | 2014-09-04 | Can-Fite Biopharma Ltd. | Procedure to induce hepatocyte proliferation and uses thereof |
| EP2806878A1 (en) * | 2012-01-23 | 2014-12-03 | Can-Fite Biopharma Ltd. | Treatment of liver conditions |
-
2015
- 2015-11-23 IL IL242723A patent/IL242723B/en active IP Right Grant
-
2016
- 2016-11-22 HR HRP20210020TT patent/HRP20210020T1/en unknown
- 2016-11-22 WO PCT/IL2016/051258 patent/WO2017090036A1/en not_active Ceased
- 2016-11-22 HU HUE16806299A patent/HUE053558T2/en unknown
- 2016-11-22 CN CN201680068558.0A patent/CN108367016B/en active Active
- 2016-11-22 IL IL289841A patent/IL289841B/en unknown
- 2016-11-22 DK DK16806299.0T patent/DK3380104T3/en active
- 2016-11-22 MX MX2018006026A patent/MX378107B/en unknown
- 2016-11-22 KR KR1020187016840A patent/KR102103657B1/en active Active
- 2016-11-22 PT PT168062990T patent/PT3380104T/en unknown
- 2016-11-22 RS RS20210079A patent/RS61372B1/en unknown
- 2016-11-22 JP JP2018526535A patent/JP6980655B2/en active Active
- 2016-11-22 EP EP16806299.0A patent/EP3380104B1/en active Active
- 2016-11-22 SI SI201631045T patent/SI3380104T1/en unknown
- 2016-11-22 ES ES16806299T patent/ES2848150T3/en active Active
- 2016-11-22 BR BR112018010391A patent/BR112018010391A8/en not_active Application Discontinuation
- 2016-11-22 LT LTEP16806299.0T patent/LT3380104T/en unknown
- 2016-11-22 PL PL16806299T patent/PL3380104T3/en unknown
- 2016-11-22 CA CA3005961A patent/CA3005961C/en active Active
-
2018
- 2018-05-16 IL IL259396A patent/IL259396B/en unknown
- 2018-05-22 US US15/986,332 patent/US10780106B2/en active Active
-
2020
- 2020-02-10 JP JP2020020917A patent/JP6990934B2/en active Active
- 2020-08-26 US US17/003,191 patent/US11291681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2010000304A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
| EP3424931A3 (en) | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein | |
| MX2019003945A (en) | CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS. | |
| MX2015012414A (en) | Salt of omecamtiv mecarbil and process for preparing salt. | |
| CL2015002635A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| CL2014000827A1 (en) | Method for isolating compound 9 - {(r) - 2 - [((s) - {[(s) -1- (isopropoxycarbonyl) ethyl] amino} phenoxyphosphinyl) methoxy] propyl} adenine using dynamic crystallization-induced resolution, with antiviral properties; and methods for preparing the intermediate compounds involved in said method. | |
| AR100215A1 (en) | ANTIBODY-DRUG CONJUGATES ANTI-PTK7 | |
| MX378107B (en) | AN A3 ADENOSINE RECEPTOR BINDER FOR USE IN THE TREATMENT OF ECTOPIC FAT ACCUMULATION. | |
| ECSP11011344A (en) | NEW ANTIBODIES ANTI-? 5? 1 AND ITS USES | |
| CL2014001309A1 (en) | Compounds derived from [1,2,3] triazolo [4,5-d] -pyrimidine, cannabinoid receptor agonists 2; obtaining process; pharmaceutical composition; use for the treatment or prophylaxis of pain, atherosclerosis, diabetic retinopathy, diabetes, liver fibrosis, heart failure, among others. | |
| BR112021020681A2 (en) | Small molecule FXR agonist and method of preparation therefor and use thereof | |
| AR064254A1 (en) | CORN EXTRACTED WITH SOLVENT | |
| MX364800B (en) | Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period. | |
| MX384427B (en) | CONCENTRATED PROTEIN COMPOSITIONS AND METHODS FOR ITS PREPARATION AND USE. | |
| UY37442A (en) | 4-SUBSTITUTED PHENYLAMINE DERIVATIVES AND ITS USE TO PROTECT CROPS WHEN FIGHTING INDESEATED PHYTOOPATHOGENIC MICROORGANISMS | |
| PE20142409A1 (en) | BALLS THAT INCLUDE STARCH AND PROTEIN, THE PROCESS FOR THESE AND THE USE OF THEM | |
| BR112015032526A2 (en) | anti-dandruff compositions and methods of use thereof | |
| IL285088A (en) | The composition containing cannabinoids, methods for its preparation and uses | |
| MX394230B (en) | CRYSTALLINE MODIFICATION OF PROPANIL. | |
| BR112015024625A2 (en) | galactooligosaccharide composition for use in the prevention or treatment of cognitive dysfunction and emotional disorders in neuropsychiatric disorders or aging | |
| MX2020008125A (en) | COMPOSITIONS COMPRISING BERBERINE. | |
| EP3285071A4 (en) | Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method | |
| MX392798B (en) | Crystals | |
| AR098035A1 (en) | FOOD COMPOSITION FOR RUMINANT ANIMALS CONTAINING PROTEINS AND PREPARATION METHOD | |
| AR097145A1 (en) | FOOD COMPOSITION IN PASTA FOR RUMINANTS AND METHOD TO PREPARE |